MS-245
MS-245 (also known as 5-methoxy-6-methyl-2-aminoindane), is a drug that is a member of the aminoindane class. It was developed in the 1990s by a team at Pfizer and has been researched for its potential use in the treatment of Alzheimer's disease and other memory related disorders.
History[edit | edit source]
MS-245 was first synthesized and studied in the 1990s by a team at Pfizer. The compound was developed as part of a series of aminoindane derivatives that were being investigated for their potential therapeutic effects.
Pharmacology[edit | edit source]
MS-245 is an NMDA receptor antagonist, which means it works by blocking the action of the NMDA receptor, a type of glutamate receptor that is involved in memory and learning. By blocking this receptor, MS-245 may help to reduce the symptoms of Alzheimer's disease and other memory related disorders.
Clinical Trials[edit | edit source]
In preclinical trials, MS-245 showed promise as a potential treatment for Alzheimer's disease. However, further research is needed to determine its efficacy and safety in humans.
See Also[edit | edit source]
References[edit | edit source]
MS-245 Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD